Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients
Peng Song(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Zhang(Fourth Hospital of Changsha), Chunxue Bai(Fudan University), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Yu Yao(Qinghai University), Faguang Jin(Tang Du Hospital), Jianping Zhao(Xinjiang University), Qi Wang(Dalian Medical University), Xiangdong Zhou(Army Medical University), Xiaoyu Zhang(Agilent Technologies (United States)), Kai Wang(Michigan United), Li Bai(Army Medical University), Jiän Zhang(Qingdao University), Xiaoxia Cui(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoju Zhang(Henan University), Xiaoli Zhu(Pulmonary Associates), Yanbin Zhou(The First Affiliated Hospital, Sun Yat-sen University)
Cited by 19
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs
|Cell stem cell|2008|4k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
The MicroRNA Spectrum in 12 Body Fluids
|Clinical Chemistry|2010|2.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k